Technology, Healthcare Dec 27, 2021 05:59 PM (GMT+8) · EqualOcean
Financial Associated Press, Dec. 27 - Guizhou bailing announced that the company's wholly-owned subsidiary Zhengxin pharmaceutical Shuangyang houbitong granule has obtained the notice of approval for supplementary application for drug clinical trial approved and issued by the State Food and drug administration, and agreed to modify and improve the clinical trial scheme to carry out the application for acute pharyngitis in children aged 6 and over Clinical trial of sore throat caused by acute tonsillitis (exogenous wind heat syndrome).